|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003241,
umls-concept:C0021006,
umls-concept:C0021051,
umls-concept:C0032594,
umls-concept:C0086418,
umls-concept:C0205151,
umls-concept:C0305065,
umls-concept:C0439849,
umls-concept:C0546816,
umls-concept:C0681850,
umls-concept:C0871261,
umls-concept:C1550501,
umls-concept:C1704632,
umls-concept:C1706203,
umls-concept:C1706817,
umls-concept:C2349001,
umls-concept:C2697811,
umls-concept:C2713304,
umls-concept:C2754943,
umls-concept:C2911692
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1996-7-25
|
|
pubmed:abstractText |
Human immunodeficiency virus (HIV)-infected persons are less likely than are noninfected persons to respond to vaccination with pneumococcal polysaccharides (PPS). Among those who respond, however, similar IgG levels may be achieved. HIV-infected men immunized with pneumococcal vaccine were classified as high- or low-level responders (IgG > or = 1 microgram/mL for > or = 3 of 5 PPS [high] or for < or = 1 PPS [low]). One and 2 years after immunization, geometric mean IgG levels and the percentages of subjects with IgG levels > or = 1 microgram/mL were similar for HIV-infected and for healthy high-level responders (controls) for all PPS except for serotype 8. Among HIV-infected low-level responders, revaccination with a double dose of pneumococcal vaccine did not stimulate IgG responses. Responsiveness of HIV-infected white patients was significantly associated with the Km(1)- negative allotype. These findings support current general recommended guidelines for administering pneumococcal vaccine to HIV-infected persons. Nonresponders will not benefit from revaccination.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0022-1899
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
173
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1347-53
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8648206-Adult,
pubmed-meshheading:8648206-Antibodies, Bacterial,
pubmed-meshheading:8648206-Antigens, Bacterial,
pubmed-meshheading:8648206-Bacterial Capsules,
pubmed-meshheading:8648206-Bacterial Vaccines,
pubmed-meshheading:8648206-HIV Infections,
pubmed-meshheading:8648206-Humans,
pubmed-meshheading:8648206-Immunization, Secondary,
pubmed-meshheading:8648206-Immunization Schedule,
pubmed-meshheading:8648206-Immunoglobulin Allotypes,
pubmed-meshheading:8648206-Immunoglobulin G,
pubmed-meshheading:8648206-Male,
pubmed-meshheading:8648206-Middle Aged,
pubmed-meshheading:8648206-Pneumococcal Infections,
pubmed-meshheading:8648206-Pneumococcal Vaccines,
pubmed-meshheading:8648206-Streptococcus pneumoniae,
pubmed-meshheading:8648206-Vaccination
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
IgG antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus-infected subjects: persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response.
|
|
pubmed:affiliation |
Medical Service, VA Medical Center, Houston, TX 77030, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, Non-P.H.S.
|
